Thomas Steyer’s Ultragenyx Pharmaceutical RARE Stock Holding History

Thomas Steyer’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,000	Closed	-$211K	–	167
2025 Q3	$211K	Sell	7,000 -891,000	-99%	-$26.7M	﹤0.01%	123
2025 Q2	$32.7M	Buy	+898,000	New	+$32.4M	0.14%	62
2024 Q4	–	Sell	-4,000	Closed	-$222K	–	165
2024 Q3	$222K	Sell	4,000 -95,000	-96%	-$4.84M	﹤0.01%	139
2024 Q2	$4.07M	Hold	99,000	–	–	0.02%	94
2024 Q1	$4.62M	Buy	+99,000	New	+$4.67M	0.02%	104

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Thomas Steyer's RARE Position: Q4 2025 in Review

Thomas Steyer sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 7,000 shares — an estimated $211K sold.

Thomas Steyer first reported a position in RARE in Q1 2024 and held it in 5 quarters. The position peaked at $32.7M in Q2 2025. 288 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

Thomas Steyer reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Thomas Steyer sold 7,000 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $211K.
Thomas Steyer first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and held it in 5 quarters.
Thomas Steyer's Ultragenyx Pharmaceutical position peaked at $32.7M in Q2 2025.
288 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Farallon Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.